About Us - 3ARx Solutions

3ARx provides insightful solutions ensuring patients’ access to innovative biopharmaceutical therapies.

Mission

To partner with biopharmaceutical companies and provide insightful solutions to promote patient access to innovative therapeutics.

Vision

To become the trusted partner of biopharmaceutical companies in advancing patient access to life-changing medical innovations.

Values

Passion for patients: We are passionate about facilitating patient access to innovative therapeutics.

Collaboration with customers: We believe in building trust through open communication and shared goals.

Excellence in execution: We strive to deliver innovative and high-quality strategic insights.

Core Team

Adel Gehchan, MD

Acting Chief Executive Officer

Chief Medical Officer

•Adel is a physician with academic and clinical experience, specializing in internal, pulmonary, and critical care medicine.

•He led medical affairs at several biopharmaceutical companies. His expertise is in inflammation/immunology, neurology, and oncology, resulting in the successful commercialization of 16 innovative products.

•He engaged KOLs in CTs*, IISs*, treatment guidelines, and clinical practice reports. He solicited their expertise and advice on strategy development, medical education, and patient support programs.

•He consults for biopharmaceutical companies.

*CTs: Clinical Trials
*IISs: Investigator-Initiated Studies

Abraham G. Hartzema, PharmD, Ph.D.

Chief Scientific Officer

•Bram is a Professor and Eminent Scholar Emeritus at the University of Florida’s College of Pharmacy. His extensive research has advanced pharmacovigilance and pharmacoepidemiology.

•He authored numerous publications and books, including 1) Post-Authorization Safety Studies of Medicinal Products: The PASS Book (recently translated into Japanese) and 2) Pharmacoepidemiology and Therapeutic Risk Management.

•He collaborated with the FDA on the Sentinel Initiative for post-marketing drug safety surveillance; he served as a Principal Investigator (PI) for observational partnership with the FDA and Pharmaceutical Research and Manufacturers (PhRMA)

•He consults for biopharmaceutical companies.

Jennifer Guo, Ph.D.

Head of Global Market Access/HEOR Communications

•Jennifer has extensive experience in the biopharmaceutical industry.

•She worked with worldwide markets (US and EU), focusing on cardiovascular disease, neurology, oncology, and hematology.

•Her expertise lies in developing strategies, defining PROs in early-stage clinical trials, leading evidence generation for HEOR, and supervising/co-authoring communications for market access.

•She has authored and co-authored numerous peer-reviewed publications on cost-effectiveness modeling, budget impact analysis, PROs, and real-world evidence.

•She consults for payers and biopharmaceutical companies.